Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:04:19 EDT Sun 19 Oct 2025
Enter Symbol
or Name
USA
CA



News last 24 hour(s) - 17 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2025-10-19 13:30U:INCYNews ReleaseIncyte Announces Phase 1 Results for its TGFbetaR2*PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
2025-10-19 12:10U:CNews ReleaseAmerican Airlines and Citi Launch the Citi / AAdvantage Globe Mastercard
2025-10-19 10:30U:SMMTNews ReleaseIvonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
2025-10-19 10:30U:JNJNews ReleaseSubcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
2025-10-19 08:45U:MRKNews ReleaseRaludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
2025-10-19 08:30U:GILDNews ReleaseGilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
2025-10-19 08:00U:REPLNews ReleaseReplimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
2025-10-19 08:00U:RAPTNews ReleaseRAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
2025-10-19 08:00U:MRNANews ReleaseModerna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
2025-10-19 07:00U:AZNNews ReleaseDATROWAY(TM) (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
2025-10-19 05:15U:CORTNews ReleaseCorcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
2025-10-19 04:15U:VSTMNews ReleaseVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
2025-10-19 04:15U:PFENews ReleaseXTANDI(TM) Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
2025-10-19 02:30U:PFENews ReleasePfizer's BRAFTOVI(TM) + MEKTOVI(TM) Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
2025-10-19 02:30U:GILDNews ReleaseTrodelvy(TM) Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
2025-10-18 16:15U:DCTHNews ReleaseDelcath Systems Announces Preliminary Third Quarter 2025 Financial Results
2025-10-18 16:13U:DCTHNews ReleaseDelcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint